1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Lonza Group AG
  6. News
  7. Summary
    LONN   CH0013841017


Delayed Swiss Exchange  -  11:31 2022-06-27 am EDT
513.00 CHF   +0.04%
06/26Lonza Signs License Deal With Adva Biotechnology For Automated Bioreactor-linked Patents
06/24LONZA : and Adva Biotechnology Ltd. Agree to Expand Availability and Use of Automated Bioreactors with License to Lonza's Patents
06/15Lonza Group Signs Manufacturing Agreement With Pierre Fabre
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EuroAPI gains on market debut after spin-off from Sanofi

05/06/2022 | 06:56am EDT
FILE PHOTO: The skyline of La Defense business district seen from Paris

(Reuters) - Shares in EuroAPI, the drug ingredients business spun off from Sanofi, rose on their Paris stock market debut on Friday, defying a wider market decline.

EuroAPI traded at around 12.25 euros at 0915 GMT, valuing the contract manufacturer's equity at 1.15 billion euros ($1.21 billion) and up 2% from its reference price of 12 euros.

The stock premiered in choppy markets, with world stocks falling towards their lowest in over a year as investors anticipated more U.S. interest rate rises and worried about the hit to growth from China's zero-COVID policy.

The STOXX Europe 600 Health Care index was down 1.7%, while France's blue chip index was off 1.5%.

"What a remarkable day it is," said EuroAPI Chief Executive Karl Rotthier after ringing the opening bell in Paris.

"It's my birthday today, that's another good start," added Rotthier, who joined in early 2020 from Dutch pharma ingredients maker Centrient Holding.

Sanofi shareholders will receive one EuroAPI share for 23 shares held in the parent company.

Sanofi shares were down 0.2%, when adjusting for EuroAPI's separation and the payout of a 4.07 billion ordinary dividend.

Sanofi, which will keep a 30% stake, distributed 58% of EuroAPI's equity capital to Sanofi shareholders as a dividend in kind. The French state will acquire 12% in the new company, based on the average market price over the next 30 days.

The group joins rivals including Siegfried and Lonza as stand-alone ingredients and services suppliers to the drugs industry.

As an independent group, EuroAPI has said it will push to win over more of Sanofi's rivals as customers and expand in high-margin drug development services.

Pharma groups that, unlike Sanofi, continue to produce drug ingredients for other drugmakers include Pfizer, Teva and family-owned Boehringer Ingelheim.

EuroAPI's flotation comes as the coronavirus pandemic and Russia's attack on Ukraine have heightened concerns in the European Union over the region's dependency on critical pharma ingredient imports.

($1 = 0.9471 euros)

(Reporting by Ludwig Burger Editing by Jason Neely and Mark Potter)

By Ludwig Burger

© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
EUROAPI 1.78% 14.55 Real-time Quote.0.00%
L'ORÉAL -0.68% 334.55 Real-time Quote.-19.21%
LONZA GROUP AG 0.04% 513 Delayed Quote.-32.67%
SANOFI -0.96% 99.59 Real-time Quote.13.52%
TEVA PHARMACEUTICAL INDUSTRIES LIMITED 0.45% 26.89 End-of-day quote.-0.22%
US DOLLAR / RUSSIAN ROUBLE (USD/RUB) 1.93% 54.4 Delayed Quote.-28.47%
All news about LONZA GROUP AG
06/26Lonza Signs License Deal With Adva Biotechnology For Automated Bioreactor-linked Patent..
06/24LONZA : and Adva Biotechnology Ltd. Agree to Expand Availability and Use of Automated Bior..
06/15Lonza Group Signs Manufacturing Agreement With Pierre Fabre
06/08Lonza Rolls Out PyroCell Monocyte Activation Test System For In Vitro Testing
06/07LONZA : More Sensitive Non-endotoxin Pyrogen Detection Now Possible with Lonza's New PyroC..
06/03AlphaValue/Baader Europe Lifts Price Target on Lonza Group, Maintains Add Recommendatio..
06/01Lonza Delivers Early Phase Clinical Manufacturing Facility in US
06/01LONZA : Completes Dedicated Early Clinical Phase Development and Manufacturing Facility in..
05/25Lonza and Israel Biotech Fund Collaboration Framework Agreement to Support Biologics an..
05/24Lonza Ties Up With Israel Biotech Fund On Biologics, Small Molecule Development, Manufa..
More news
Analyst Recommendations on LONZA GROUP AG
More recommendations
Sales 2022 6 146 M 6 433 M 6 433 M
Net income 2022 1 068 M 1 118 M 1 118 M
Net cash 2022 255 M 266 M 266 M
P/E ratio 2022 35,7x
Yield 2022 0,65%
Capitalization 38 044 M 39 826 M 39 826 M
EV / Sales 2022 6,15x
EV / Sales 2023 5,47x
Nbr of Employees 16 218
Free-Float 99,6%
Duration : Period :
Lonza Group AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 19
Last Close Price 512,80 CHF
Average target price 793,37 CHF
Spread / Average Target 54,7%
EPS Revisions
Managers and Directors
Pierre-Alain Ruffieux Chief Executive Officer
Philippe Deecke Chief Financial Officer
Albert M. Baehny Chairman
Stefan Stoffel Head-Small Molecules Exclusive Synthesis Operation
Barbara May Richmond Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LONZA GROUP AG-32.67%39 851
MODERNA, INC.-43.20%57 385
IQVIA HOLDINGS INC.-24.22%40 468
SEAGEN INC.16.00%33 010
CELLTRION, INC.-13.38%18 371